Investment Thesis
CTT Pharmaceutical Holdings is an effectively dormant company with no revenue generation, persistent operating losses, and severely depleted cash reserves ($32.1K). The company is burning cash at an unsustainable rate (-$84.3K operating cash flow) while showing no path to profitability or operational recovery. The dramatic mismatch between its sector classification (Gold and Silver Ores) and company name (Pharmaceutical) suggests potential shell company status or significant business discontinuation.
Strengths
- Strong current ratio of 3.70x indicates short-term liquidity position relative to liabilities
- Zero long-term debt eliminates financial leverage risk
- Positive stockholders equity of $738.1K provides theoretical going concern basis
Risks
- Complete absence of revenue with no indication of business operations
- Negative operating cash flow of -$84.3K combined with minimal cash reserves of $32.1K indicates imminent liquidity crisis
- Severely negative ROE (-141.1%) and ROA (-113.0%) demonstrate destruction of shareholder capital
- Stale financial data from September 2015 (10+ years old) prevents current viability assessment
- Sector-company name mismatch suggests dormant or shell company status with no active business
- No insider activity in past 90 days suggests abandonment of the company
Key Metrics to Watch
- Operating cash flow trend and cash depletion rate
- Any revenue generation or new business operations
- Updated financial filings and company status with SEC
Financial Metrics
Revenue
N/A
Net Income
-1.0M
EPS (Diluted)
$0.00
Free Cash Flow
-84.3K
Total Assets
922.0K
Cash
32.1K
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-141.1%
ROA
-113.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
3.70x
Quick Ratio
3.70x
Debt/Equity
0.00x
Debt/Assets
20.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-23T04:36:11.477532 |
Data as of: 2015-09-30 |
Powered by Claude AI